Sera Prognostics reports Q4/FY2023 results; DSMB stops PRIME study early for efficacy

SERA PROGNOSTICS, INC.

DSMB recommended stopping PRIME enrollment after co-primary endpoints met significance at interim analysis; preparing manuscript.
Q4 2023 revenue $41K; full-year revenue $306K; net loss $7.9M (Q4) and $36.2M (FY), improved from prior year.
Operating expenses down to $8.9M (Q4) from $10.5M; SG&A reduced to $5.0M from $6.9M.
Cash and securities $79.9M as of Dec 31, 2023.
Progress on PreTRM sample collection enhancements; launching in certain geographies; building patient-facing products.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

SERA PROGNOSTICS, INC. reported financial results for the fourth quarter and fiscal year ended December 31, 2023.

Period: the fourth quarter and fiscal year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 20, 2024, Sera Prognostics, Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023 and providing business highlights.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

SERA PROGNOSTICS, INC. filing history →

Source: SEC EDGAR

accession 0001534969-24-000054

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.